Barinthus Biotherapeutics (Barinthus Biotherapeutics) Net Issuance of Debt : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Barinthus Biotherapeutics Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Barinthus Biotherapeutics's net issuance of debt for the three months ended in Mar. 2024 was $0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Barinthus Biotherapeutics Net Issuance of Debt Historical Data

The historical data trend for Barinthus Biotherapeutics's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Barinthus Biotherapeutics Net Issuance of Debt Chart

Barinthus Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Debt

41.24

-0.16

Barinthus Biotherapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Issuance of Debt	Get a 7-Day Free Trial												-	-	-	-	-

Barinthus Biotherapeutics Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Barinthus Biotherapeutics Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Barinthus Biotherapeutics's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Barinthus Biotherapeutics (Barinthus Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Barinthus Biotherapeutics PLC (NAS:BRNS) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 6-10, Rutherford Avenue, Zeus Building, Harwell, Didcot, GBR, OX11 0DF

Website

https://www.barinthusbio.com

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.

Executives

Joseph Scheeren	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Robin Wright	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
William Enright	director, officer: Chief Executive Officer	910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Nadege Pelletier	officer: Chief Scientific Officer	C/O VACCITECH PLC, UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Gemma Brown	officer: Chief Financial Officer	VACCITECH PLC, UNIT 6-10, ZEUS BUILDING, RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Graham Griffiths	officer: Chief Business Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Christopher Ellis	officer: Chief Operating Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Anne M. Phillips	director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Oxford Science Enterprises Plc	10 percent owner	46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT
Karen A Dawes	director	579 BELLEVUE AVE, NEWPORT RI 02840
Pierre A. Morgon	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Margaret Marshall	officer: Chief Medical Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Thomas George Evans	officer: Chief Scientific Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Alex Hammacher	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Georgy Egorov	officer: Chief Financial Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE